De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Nov 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to treating triple negative breast cancer (TNBC) by combining immunotherapy with less intense chemotherapy. Traditionally, patients have received a strong chemotherapy regimen that can lead to significant side effects and long treatment cycles. The trial aims to find out if a reduced chemotherapy plan, still paired with immunotherapy, can effectively treat patients while minimizing side effects. Researchers will compare the results of these different treatment plans using a large database of patients from Peking University People's Hospital.

To be eligible for this trial, participants must have been diagnosed with TNBC, specifically at stage II or III, meaning their cancer may have spread to nearby lymph nodes but not to distant organs. They also need to have received treatment at this hospital and agreed to join the study. Participants can expect close monitoring of their health and treatment responses, and they will be contributing to important research that could help improve future TNBC treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1) Patients with triple negative breast cancer diagnosed by biopsy in Peking University People's Hospital;
• • 2) The clinical stage was stage II or stage III (i.e. T2 and above, and/or lymph node positive, without distant organ metastasis);
• • 3) Received treatment in our hospital and had hospitalization records;
• • 4) Has signed and agreed to participate in the PKUPH breast disease cohort study.
• Exclusion Criteria:
• • 1) Lack of clinical and pathological data (such as imaging data and pathological data);
• • 2) Patients with metastatic breast cancer or bilateral breast cancer;
• • 3) At the same time, they received anti-tumor therapy in other clinical trials, including endocrine therapy and targeted therapy;
• • 4) Receiving other regimens besides the established neoadjuvant regimens